|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 1 | 2022 | Cognitive improvements accompanied with WPAI improvements in OCR-treated patients with RRMS: 96-week CASTING data | Vermersch, P.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuenzel, T.; Benedict, R. | Journal Contribution | M |
| 2 | 2022 | Safety of Alemtuzumab in Patients with Multiple Sclerosis: Interim Results of a Post-Authorization Safety Study (PASS) | Montalban, X.; VAN WIJMEERSCH, Bart; Gobbi, C.; Robertson, N.; Klotz, L.; Achiron, A.; Lee, A.; Eichau, S.; Vecsei, L.; Benzerdjeb, H.; Rodrigues, A.; Jurgensen, S.; Chirieac, M.; Comi, G. | Journal Contribution | M |
| 3 | 2022 | Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO | Oreja-Guevara, C.; Benedict, R. H.; Comi, G.; Cutter, G.; Kister, I.; Siva, A.; Wiendl, H.; VAN WIJMEERSCH, Bart; Wuerfel, J.; El Azzouzi, B.; Buffels, R.; Dirks, P.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 4 | 2022 | Cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data | Benedict, R. H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 5 | 2022 | Employment and cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data | Wiendl, H.; Benedict, R. H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Buffels, R.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 6 | 2022 | Employment and Cognitive Improvements in Ocrelizumab-Treated Patients with Relapsing-Remitting Multiple Sclerosis: 96-Week CASTING Study Data | Wiendl, H.; Benedict, R.H.B.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Buffels, R.; Kuenzel, T.; Vermersch, P. | Conference Material | C2 |
| 7 | 2021 | Efficacy and safety of ocrelizumab in patients with RRMS with suboptimal response to prior disease-modifying therapies: 3-year data from CASTING and LIBERTO 1-year interim results | VAN WIJMEERSCH, Bart; Comi, G.; Oreja-Guevara, C.; Wiendl, H.; Wuerfel, J.; Buffels, R.; Dirks, P.; Kuenzel, T.; Kadner, K.; Vermersch, P. | Journal Contribution | M |
| 8 | 2020 | Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) | Hartung, H-P; Comi, G.; Arnold, D. L.; Boyko, A. N.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 9 | 2020 | Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results) | Vermersch, P.; Eralinna, J.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Wei, W.; Comi, G. | Journal Contribution | M |
| 10 | 2020 | Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ) | Ziemssen, T.; Bass, A. D.; Berkovich, R.; Eichau, S.; Hobart, J.; Hunter, S. F.; Limmroth, V.; Pelletier, D.; Pozzilli, C.; Schippling, S.; Singer, B. A.; Sousa, L.; Traboulsee, A.; Uittlehaag, B. M. J.; VAN WIJMEERSCH, Bart; Poole, E. M.; Choudhry, Z.; Geertsen, S.; Daizadeh, N.; Comi, G. | Journal Contribution | M |
| 11 | 2020 | Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts | Wiendl, H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wuerfel, J.; Buffels, R.; Kadner, K.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 12 | 2019 | Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study) | Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H. -P.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 13 | 2019 | Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years | Vermersch, P.; Baker, M.; Bass, A. D.; Berkovich, R.; Comi, G.; Eichau, S.; Graves, D.; Hunter, S. F.; Ionete, C.; Limmroth, V.; Meuth, S. G.; Naismith, R. T.; Sharrack, B.; Subei, A.; Daizadeh, N.; Choudhry, Z.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 14 | 2019 | Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) | McCombe, P.; Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H-P; Havrdova, E. K.; Inshasi, J. S.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 15 | 2019 | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results) | Vermersch, P.; Eralinna, J. -P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W.; Comi, G. | Journal Contribution | M |
| 16 | 2018 | Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extension | VAN WIJMEERSCH, Bart; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; Jacobs, Alessia; Wiendl, H. | Journal Contribution | M |
| 17 | 2018 | Durable suppression of MRI disease activity and slowing of brain volume loss in alemtuzumab-treated patients with active RRMS: 7-year follow-up of CARE-MS I (TOPAZ Study) | Schippling, S.; Arnold, D.; Barnett, M.; Comi, G.; Laganke, C.; Rovira, A.; Traboulsee, A.; Melanson, M.; Daizadeh, N.; Nakamura, K.; VAN WIJMEERSCH, Bart; Pelletier, D. | Journal Contribution | M |
| 18 | 2018 | Lack of apparent association between lymphocyte repopulation kinetics and autoimmune events in alemtuzumab-treated patients with relapsing-remitting Multiple Sclerosis through 6 years: CARE-MS extension | Wiendl, H.; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; JACOBS, Andre; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 19 | 2018 | No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 20 | 2018 | No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
Loading...
5
0
5
0
false